Effects of Chocolate on Motor Symptoms of Parkinson's Disease

Not Applicable

• Conditions: Parkinson's Disease
• Interventions: Dietary Supplement: Chocolate

• Registration Number: NCT00906763
• Lead Sponsor: Technische Universität Dresden

Brief Summary

Chocolate consumption has long been associated with enjoyment and pleasure. Popular claims confer on chocolate the properties of being a stimulant, relaxant, euphoriant and antidepressant. These possible pharmacological actions might be related to various biogenic amines, such as serotonin, dopamine, tyramine, histamine, phenylethylamine and cannabinoid-like substances. Most amines are metabolized by monoamineoxidase-A (MAO-A) and are therefore unable to pass the blood-brain-barrier. In contrast, phenylethylamine is a direct dopamine releasing ingredient and as a substrate of MAO-B and due to its lipophilic structure even capable to pass the blood-brain-barrier. Within this line, own clinical observations suggested an increased chocolate consumption in patients with Parkinson's disease (PD) compared to healthy subjects and to their pre-disease state.

In a previous study, we assessed the consumption of chocolate and non-chocolate sweets in PD patients and their partners (as household controls) using a self-questionnaire. Consumption of chocolate was significantly higher in PD patients compared to controls, while consumption of non-chocolate sweets was similar in both groups. Our study suggests that chocolate consumption is increased in PD independent of concomitant depressive symptoms measured by BDI-1. Although reasons for increased chocolate consumption in PD remain elusive, it may hypothetically be a consequence of the high content of various biogenic amines as a content of cocoa influencing dopamine metabolism.

Therefore, in the present study we aim to study the effects of dark chocolate with high cocoa content (85%) compared to chocolate without any cocoa (white chocolate) on motor symptoms in PD patients as measured with UPDRS part III (motor score). The principle design of the intervention is similar to the standard pharmacological challenge test for studying effects on motor symptoms in PD (e.g. levodopa challenge test).

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05
• Study First Submitted: 2009-05-20
• Study First Submitted QC: 2009-05-20
• Study First Posted: 2009-05-21
• Status Verified: 2010-05
• Last Update Submitted: 2010-05-25
• Last Update Posted: 2010-05-26
• Primary Completion: 2010-08
• Study Completion: 2010-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

• Age of 18 Years or older
• Idiopathic Parkinson's disease, according to UKBB criteria
• Hoehn & Yahr Score II-III
• 16 Points or more in UPDRS part III scale
• Sufficient ability to follow the study procedure for at least 3 hours
• Ability to give informed consent
• Stable antiparkinsonian medication for at least 4 weeks prior to study inclusion

Exclusion Criteria

• Psychiatric conditions, severe enough to interfere with study procedures
• motor or affective fluctuations or dyskinesias
• treatment with COMT and/or MAO inhibitors
• Diabetes mellitus

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Dark Chocolate (85% cocoa)	Chocolate	Oral Intake of dark chocolate (85% cocoa) over 15 minutes.
White chocolate (0% cocoa)	Chocolate	Oral intake of 200 grams of white chocolate (0% cocoa) over 15 Minutes.

Primary Outcome Measures

Name	Time	Method
UPDRS part III	1 h after intake of study intervention

Secondary Outcome Measures

Name	Time	Method
Biogenic amines in blood	1 to 3 h after study intervention

Trial Locations

Locations (1)

Dresden University of Technology, Medical Faculty; 🇩🇪 Dresden, Germany